263 related articles for article (PubMed ID: 18565126)
1. Properties of a concentrated minipool solvent-detergent treated cryoprecipitate processed in single-use bag systems.
Burnouf T; Caron C; Radosevich M; Goubran HA; Goudemand J; El-Ekiaby M
Haemophilia; 2008 Sep; 14(5):956-62. PubMed ID: 18565126
[TBL] [Abstract][Full Text] [Related]
2. A minipool process for solvent-detergent treatment of cryoprecipitate at blood centres using a disposable bag system.
Burnouf T; Goubran HA; Radosevich M; Sayed MA; Gorgy G; El-Ekiaby M
Vox Sang; 2006 Jul; 91(1):56-62. PubMed ID: 16756602
[TBL] [Abstract][Full Text] [Related]
3. Solvent-detergent filtered (S/D-F) fresh frozen plasma and cryoprecipitate minipools prepared in a newly designed integral disposable processing bag system.
El-Ekiaby M; Sayed MA; Caron C; Burnouf S; El-Sharkawy N; Goubran H; Radosevich M; Goudemand J; Blum D; de Melo L; Soulié V; Adam J; Burnouf T
Transfus Med; 2010 Feb; 20(1):48-61. PubMed ID: 19778318
[TBL] [Abstract][Full Text] [Related]
4. A process for solvent/detergent treatment of plasma for transfusion at blood centers that use a disposable-bag system.
Burnouf T; Goubran HA; Radosevich M; Sayed MA; Gorgy G; El-Ekiaby M
Transfusion; 2006 Dec; 46(12):2100-8. PubMed ID: 17176321
[TBL] [Abstract][Full Text] [Related]
5. Comparison of coagulation factor XIII content and concentration in cryoprecipitate and fresh-frozen plasma.
Caudill JS; Nichols WL; Plumhoff EA; Schulte SL; Winters JL; Gastineau DA; Rodriguez V
Transfusion; 2009 Apr; 49(4):765-70. PubMed ID: 19192257
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic study of minipooled solvent/detergent-filtered cryoprecipitate factor VIII.
El-Ekiaby M; Goubran HA; Radosevich M; Abd-Allah A; El-Ekiaby A; Burnouf T
Haemophilia; 2011 Sep; 17(5):e884-8. PubMed ID: 21371202
[TBL] [Abstract][Full Text] [Related]
7. [Solvent-detergent viral inactivation of minipools of plasma for transfusion, cryoprecipitate and cryo-poor plasma in single-use bag systems].
Burnouf T; Goubran HA; Radosevich M; El-Ekiaby M
Transfus Clin Biol; 2008 Jun; 15(3):129-34. PubMed ID: 18538608
[TBL] [Abstract][Full Text] [Related]
8. Dengue virus inactivation by minipool TnBP/Triton X-45 treatment of plasma and cryoprecipitate.
Burnouf T; Chou ML; Cheng LH; Li ZR; Wu YW; El-Ekiaby M; Tsai KH
Vox Sang; 2013 Jan; 104(1):1-6. PubMed ID: 22758375
[TBL] [Abstract][Full Text] [Related]
9. Cryoprecipitate prepared from plasma frozen within 24 hours after phlebotomy contains acceptable levels of fibrinogen and VIIIC.
Yazer MH; Triulzi DJ; Hassett AC; Kiss JE
Transfusion; 2010 May; 50(5):1014-8. PubMed ID: 20003046
[TBL] [Abstract][Full Text] [Related]
10. Stability of coagulation factors in thawed, solvent/detergent-treated plasma during storage at 4 degrees C for 6 days.
Buchta C; Felfernig M; Höcker P; Macher M; Körmöczi GF; Quehenberger P; Heinzl H; Knöbl P
Vox Sang; 2004 Oct; 87(3):182-6. PubMed ID: 15569070
[TBL] [Abstract][Full Text] [Related]
11. A solvent/detergent-treated and 15-nm filtered factor VIII: a new safety standard for plasma-derived coagulation factor concentrates.
Chtourou S; Porte P; Nogré M; Bihoreau N; Cheesman E; Samor B; Sauger A; Raut S; Mazurier C
Vox Sang; 2007 May; 92(4):327-37. PubMed ID: 17456157
[TBL] [Abstract][Full Text] [Related]
12. Quantitative and qualitative analysis of coagulation factors in cryoprecipitate prepared from fresh-frozen plasma inactivated with amotosalen and ultraviolet A light.
Cid J; Caballo C; Pino M; Galan AM; Martínez N; Escolar G; Diaz-Ricart M
Transfusion; 2013 Mar; 53(3):600-5. PubMed ID: 22738354
[TBL] [Abstract][Full Text] [Related]
13. Characterisation of a novel high-purity, double virus inactivated von Willebrand Factor and Factor VIII concentrate (Wilate).
Stadler M; Gruber G; Kannicht C; Biesert L; Radomski KU; Suhartono H; Pock K; Neisser-Svae A; Weinberger J; Römisch J; Svae TE
Biologicals; 2006 Dec; 34(4):281-8. PubMed ID: 16500114
[TBL] [Abstract][Full Text] [Related]
14. Impact of Triton X-100 on alpha 2-antiplasmin (SERPINF2) activity in solvent/detergent-treated plasma.
Burnouf T; Goubran HA; Radosevich M; Sayed MA; Gorgy G; El-Ekiaby M
Biologicals; 2007 Oct; 35(4):349-53. PubMed ID: 17656111
[TBL] [Abstract][Full Text] [Related]
15. Cryoprecipitate prepared from plasma virally inactivated by the solvent detergent method.
Keeling DM; Luddington R; Allain JP; Lawrie AS; Williamson LM
Br J Haematol; 1997 Jan; 96(1):194-7. PubMed ID: 9012709
[TBL] [Abstract][Full Text] [Related]
16. Effect of temperature on plasma freezing under industrial conditions.
Bravo MI; Grancha S; Jorquera JI
Pharmeur Sci Notes; 2006 Aug; 2006(1):31-5. PubMed ID: 17694644
[TBL] [Abstract][Full Text] [Related]
17. Coagulation factor content of cryoprecipitate prepared from methylene blue plus light virus-inactivated plasma.
Hornsey VS; Krailadsiri P; MacDonald S; Seghatchian J; Williamson LM; Prowse CV
Br J Haematol; 2000 Jun; 109(3):665-70. PubMed ID: 10886222
[TBL] [Abstract][Full Text] [Related]
18. Plasma and cryoprecipitate manufactured from whole blood held overnight at room temperature meet quality standards.
Serrano K; Scammell K; Weiss S; Culibrk B; Levin E; Gyöngyössy-Issa M; Devine DV
Transfusion; 2010 Feb; 50(2):344-53. PubMed ID: 19843287
[TBL] [Abstract][Full Text] [Related]
19. Cryoprecipitate prepared from plasma treated with methylene blue plus light: increasing the fibrinogen concentration.
Hornsey VS; Young DA; Docherty A; Hughes W; Prowse CV
Transfus Med; 2004 Oct; 14(5):369-74. PubMed ID: 15500456
[TBL] [Abstract][Full Text] [Related]
20. [Factor VIII:C activity during heat inactivation of viruses in cryoprecipitates].
Grgicević D; Flego I; Marchiotti I; Lupret L; Rajninger-Miholić M
Lijec Vjesn; 1990; 112(7-8):212-5. PubMed ID: 2127297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
